Evoke Pharma Inc (EVOK)

$0.51

-0.02

(-3.77%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $0.50
    $0.52
    $0.51
    downward going graph

    1.76%

    Downside

    Day's Volatility :4.55%

    Upside

    2.84%

    downward going graph
  • $0.40
    $1.75
    $0.51
    downward going graph

    21.57%

    Downside

    52 Weeks Volatility :77.14%

    Upside

    70.86%

    downward going graph

Returns

PeriodEvoke Pharma IncIndex (Russel 2000)
3 Months
16.7%
0.0%
6 Months
-25.21%
0.0%
1 Year
-68.72%
0.0%
3 Years
-96.25%
-19.6%

Highlights

Market Capitalization
4.7M
Book Value
$0.41
Earnings Per Share (EPS)
-1.83
PEG Ratio
-0.1
Wall Street Target Price
7.0
Profit Margin
-116.76%
Operating Margin TTM
-86.5%
Return On Assets TTM
-37.66%
Return On Equity TTM
-253.55%
Revenue TTM
6.1M
Revenue Per Share TTM
1.28
Quarterly Revenue Growth YOY
114.19999999999999%
Gross Profit TTM
2.1M
Diluted Eps TTM
-1.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.08
EPS Estimate Next Year
0.1
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Evoke Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1272.55%

Current $0.51
Target $7.00

Technicals Summary

Sell

Neutral

Buy

Evoke Pharma Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Evoke Pharma Inc
Evoke Pharma Inc
-5.35%
-25.21%
-68.72%
-96.25%
-96.4%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
9.03%
4.21%
45.66%
48.47%
67.79%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
3.12%
5.95%
2.3%
20.24%
20.24%
Zoetis Inc.
Zoetis Inc.
3.92%
-6.6%
-3.77%
-10.95%
54.03%
Viatris Inc.
Viatris Inc.
13.09%
1.72%
11.49%
-14.51%
-27.54%
Catalent, Inc.
Catalent, Inc.
2.55%
16.24%
20.8%
-49.73%
5.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Evoke Pharma Inc
Evoke Pharma Inc
NA
NA
-0.1
-0.08
-2.54
-0.38
NA
0.41
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.17
39.17
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.7
29.7
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.47
34.47
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Evoke Pharma Inc
Evoke Pharma Inc
Buy
$4.7M
-96.4%
NA
-116.76%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.5B
67.79%
39.17
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.7B
20.24%
29.7
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.8B
54.03%
34.47
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.9B
-27.54%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
5.41%
211.02
-28.44%

Insights on Evoke Pharma Inc

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 796.37K → 1.73M (in $), with an average increase of 13.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -1.98M → -1.57M (in $), with an average increase of 25.8% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 47.5% return, outperforming this stock by 116.4%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 48.5% return, outperforming this stock by 144.8%

Institutional Holdings

  • AIGH Capital Management, LLC

    9.85%
  • Bleichroeder LP

    9.60%
  • Altium Capital Management, LP

    8.43%
  • Nantahala Capital Management, LLC

    7.85%
  • Vanguard Group Inc

    0.35%
  • Geode Capital Management, LLC

    0.31%

Company Information

evoke pharma is a biotechnology company located in 505 lomas santa fe dr, solana beach, california, united states.

Organization
Evoke Pharma Inc
Employees
4
CEO
Mr. Matthew J. D'Onofrio MBA
Industry
Health Technology

FAQs